7-Keto® is a clinically tested, patented ingredient that slows the impact of diet and age-related weight gain. "Humanetics developed and established the science and value of the 7-Keto® brand over the past twenty years," said Ronald Zenk, President and CEO of Humanetics Corporation. "We have invested heavily in clinical research and believe that 7-Keto® is one of the most scientifically sound products on the market." He added, "We believe InterHealth will continue to strengthen the 7-Keto® brand, and that this transaction will allow Humanetics to focus on its strong portfolio of ongoing pharmaceutical development initiatives."
"7-Keto® fits very nicely into InterHealth’s portfolio of science-based, branded, functional ingredients supported by robust clinical trial and safety data," according to Paul Dijkstra, President and CEO of InterHealth. "7-Keto® is sold to many of the industry’s most successful finished product brands and holds a strong position in the marketplace."
Humanetics will retain the rights to continue development of the 7-Keto® technology as a promising treatment for post-traumatic stress disorder. A clinical study at the Bay Pines Veteran’s Administration Hospital in Bay Pines Florida is expected to be completed in late 2014. Humanetics will partner with InterHealth as its supply partner in the further development of this application.